$250M Convertible Note Offering Priced by Nuvation Bio, Upsized from $200M
NUVB has more than doubled off its 52-week low of $1.81 on elevated volume (5.5× avg).
Summary
Nuvation Bio has priced an upsized offering of $250 million in 0.75% Convertible Senior Notes due 2032. This represents an increase from the $200 million offering initially proposed yesterday. The company expects to receive approximately $241.2 million in net proceeds, which will be used to repay a senior secured loan and for general corporate purposes. The notes have an initial conversion price of $7.84 per share, a 35% premium to the current stock price, which helps manage potential dilution. The sale is expected to close on June 30, 2026.
At the time of this announcement, NUVB was trading at $5.77 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $1.81 to $9.75. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: PR Newswire.